Phase I Study of the Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Bortezomib (Primary) ; Sorafenib (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 21 Mar 2025 Planned End Date changed from 7 Mar 2025 to 19 Mar 2026.
- 07 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 24 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov. .